High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?

Yıl: 2019 Cilt: 16 Sayı: 3 Sayfa Aralığı: 180 - 186 Metin Dili: İngilizce DOI: 10.4274/tjod.galenos.2019.04578 İndeks Tarihi: 04-11-2020

High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?

Öz:
Objective: To evaluate the necessity of adjuvant therapy and other prognostic factors in high-grade uterine corpus-confined endometrial cancer (EC) with lymphadenectomy performed.Materials and Methods: This study included 120 patients who had endometrioid-type grade 3, serous-type, clear cell-type, and undifferentiated-type EC and underwent lymphadenectomy.Results: Patients with high-grade uterine corpus-confined EC who underwent lymphadenectomy were evaluated. The modality of adjuvant therapy performed was not a predictor for the site of recurrence. The loco-regional recurrence rate decreased from 9.5% to 3.8% in patients who received radiotherapy. However, this difference was not statistically significant (p=0.206). In addition, performing adjuvant chemotherapy did not alter the risk of extrapelvic recurrence. Only International Federation of Gynecology and Obstetrics 2009 stage was significant in the univariate analysis. On the other hand, age, tumor type, number of removed lymph nodes, presence of myometrial and lymphovascular space invasion, tumor size and adjuvant therapy modality were not related with disease-free survival.Conclusion: Performing adjuvant therapy and therapy modality does not improve oncologic outcomes in intermediate and high-risk patients. However, radiotherapy reduced the risk of local recurrence by more than 50%. Vaginal brachytherapy was efficient as external beam radiotherapy. Therefore, vaginal brachytherapy should be used for these patients in order to reduce loco-regional recurrence even if it is not reported to be effective on disease-free survival.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
  • 2. Richman DM, Tirumani SH, Hornick JL, Fuchs CS, Howard S, Krajewski K, et al. Beyond gastric adenocarcinoma: Multimodality assessment of common and uncommon gastric neoplasms. Abdom Radiol (NY) 2017;42:124-140.
  • 3. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(8 Suppl):2035-41.
  • 4. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol 2010;116:1141-9.
  • 5. Announcements: FIGO (the International Federation of Obstetricians and Gynecologists) stages: 1988 revision. Gynecol Oncol 1989;35:125-6.
  • 6. Meeting Report. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol 2009;115:325-8.
  • 7. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11.
  • 8. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51.
  • 9. Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816-23.
  • 10. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19:295-309.
  • 11. Gupta V, McGunigal M, Prasad-Hayes M, Kalir T, Liu J. Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: A national cancer data base analysis. Gynecol Oncol 2017;144:119-24.
  • 12. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al., Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e631-8.
APA Kilic C, Çakır C, Yüksel D, Durmuş Y, Boran N, Kimyon Comert G, Karalok A, Boyraz G, TURAN T (2019). High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. , 180 - 186. 10.4274/tjod.galenos.2019.04578
Chicago Kilic Cigdem,Çakır Caner,Yüksel Dilek,Durmuş Yasin,Boran Nurettin,Kimyon Comert Gunsu,Karalok Alper,Boyraz Gokhan,TURAN Taner Ahmet High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. (2019): 180 - 186. 10.4274/tjod.galenos.2019.04578
MLA Kilic Cigdem,Çakır Caner,Yüksel Dilek,Durmuş Yasin,Boran Nurettin,Kimyon Comert Gunsu,Karalok Alper,Boyraz Gokhan,TURAN Taner Ahmet High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. , 2019, ss.180 - 186. 10.4274/tjod.galenos.2019.04578
AMA Kilic C,Çakır C,Yüksel D,Durmuş Y,Boran N,Kimyon Comert G,Karalok A,Boyraz G,TURAN T High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. . 2019; 180 - 186. 10.4274/tjod.galenos.2019.04578
Vancouver Kilic C,Çakır C,Yüksel D,Durmuş Y,Boran N,Kimyon Comert G,Karalok A,Boyraz G,TURAN T High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. . 2019; 180 - 186. 10.4274/tjod.galenos.2019.04578
IEEE Kilic C,Çakır C,Yüksel D,Durmuş Y,Boran N,Kimyon Comert G,Karalok A,Boyraz G,TURAN T "High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?." , ss.180 - 186, 2019. 10.4274/tjod.galenos.2019.04578
ISNAD Kilic, Cigdem vd. "High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?". (2019), 180-186. https://doi.org/10.4274/tjod.galenos.2019.04578
APA Kilic C, Çakır C, Yüksel D, Durmuş Y, Boran N, Kimyon Comert G, Karalok A, Boyraz G, TURAN T (2019). High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. Turkish Journal of Obstetrics and Gynecology, 16(3), 180 - 186. 10.4274/tjod.galenos.2019.04578
Chicago Kilic Cigdem,Çakır Caner,Yüksel Dilek,Durmuş Yasin,Boran Nurettin,Kimyon Comert Gunsu,Karalok Alper,Boyraz Gokhan,TURAN Taner Ahmet High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. Turkish Journal of Obstetrics and Gynecology 16, no.3 (2019): 180 - 186. 10.4274/tjod.galenos.2019.04578
MLA Kilic Cigdem,Çakır Caner,Yüksel Dilek,Durmuş Yasin,Boran Nurettin,Kimyon Comert Gunsu,Karalok Alper,Boyraz Gokhan,TURAN Taner Ahmet High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. Turkish Journal of Obstetrics and Gynecology, vol.16, no.3, 2019, ss.180 - 186. 10.4274/tjod.galenos.2019.04578
AMA Kilic C,Çakır C,Yüksel D,Durmuş Y,Boran N,Kimyon Comert G,Karalok A,Boyraz G,TURAN T High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. Turkish Journal of Obstetrics and Gynecology. 2019; 16(3): 180 - 186. 10.4274/tjod.galenos.2019.04578
Vancouver Kilic C,Çakır C,Yüksel D,Durmuş Y,Boran N,Kimyon Comert G,Karalok A,Boyraz G,TURAN T High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?. Turkish Journal of Obstetrics and Gynecology. 2019; 16(3): 180 - 186. 10.4274/tjod.galenos.2019.04578
IEEE Kilic C,Çakır C,Yüksel D,Durmuş Y,Boran N,Kimyon Comert G,Karalok A,Boyraz G,TURAN T "High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?." Turkish Journal of Obstetrics and Gynecology, 16, ss.180 - 186, 2019. 10.4274/tjod.galenos.2019.04578
ISNAD Kilic, Cigdem vd. "High-grade uterine corpus-confined endometrial cancer with lymphadenectomy: does adjuvant therapy improve survival?". Turkish Journal of Obstetrics and Gynecology 16/3 (2019), 180-186. https://doi.org/10.4274/tjod.galenos.2019.04578